JP6687525B2 - オピオイド受容体結合剤およびその使用 - Google Patents

オピオイド受容体結合剤およびその使用 Download PDF

Info

Publication number
JP6687525B2
JP6687525B2 JP2016549076A JP2016549076A JP6687525B2 JP 6687525 B2 JP6687525 B2 JP 6687525B2 JP 2016549076 A JP2016549076 A JP 2016549076A JP 2016549076 A JP2016549076 A JP 2016549076A JP 6687525 B2 JP6687525 B2 JP 6687525B2
Authority
JP
Japan
Prior art keywords
binding agent
receptor
seq
binding
opioid receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016549076A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017506505A5 (enExample
JP2017506505A (ja
Inventor
ステヤート，ジャン
ラエレマンズ，トゥーン
パルドン，エルス
コビルカ，ブライアン
マングリク，アシシュ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vlaams Instituut voor Biotechnologie VIB
Vrije Universiteit Brussel VUB
Original Assignee
Vlaams Instituut voor Biotechnologie VIB
Vrije Universiteit Brussel VUB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vlaams Instituut voor Biotechnologie VIB, Vrije Universiteit Brussel VUB filed Critical Vlaams Instituut voor Biotechnologie VIB
Publication of JP2017506505A publication Critical patent/JP2017506505A/ja
Publication of JP2017506505A5 publication Critical patent/JP2017506505A5/ja
Application granted granted Critical
Publication of JP6687525B2 publication Critical patent/JP6687525B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
JP2016549076A 2014-01-30 2015-01-30 オピオイド受容体結合剤およびその使用 Active JP6687525B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461933742P 2014-01-30 2014-01-30
US61/933,742 2014-01-30
PCT/EP2015/051991 WO2015121092A1 (en) 2014-01-30 2015-01-30 Opioid receptor binding agents and uses thereof

Publications (3)

Publication Number Publication Date
JP2017506505A JP2017506505A (ja) 2017-03-09
JP2017506505A5 JP2017506505A5 (enExample) 2018-03-08
JP6687525B2 true JP6687525B2 (ja) 2020-04-22

Family

ID=52434839

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016549076A Active JP6687525B2 (ja) 2014-01-30 2015-01-30 オピオイド受容体結合剤およびその使用

Country Status (6)

Country Link
US (2) US10233241B2 (enExample)
EP (1) EP3099707B1 (enExample)
JP (1) JP6687525B2 (enExample)
AU (1) AU2015217846B2 (enExample)
CA (1) CA2936728C (enExample)
WO (1) WO2015121092A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201014715D0 (en) 2010-09-06 2010-10-20 Vib Vzw Nanobodies stabilizing functional conformational states of GPCRS
CA2936728C (en) 2014-01-30 2023-06-20 Vib Vzw Opioid receptor binding agents and uses thereof
GB201601690D0 (en) 2016-01-29 2016-03-16 Heptares Therapeutics Ltd G proteins
US11668021B2 (en) 2017-05-09 2023-06-06 Yale University Basehit, a high-throughput assay to identify proteins involved in host-microbe interaction
CN111526887B (zh) 2017-10-11 2023-12-01 南京传奇生物科技有限公司 用于使血清中的蛋白质半衰期增加的组合物和方法
EP3963328A1 (en) * 2019-04-29 2022-03-09 Confo Therapeutics N.V. Chimeric proteins and methods to screen for compounds and ligands binding to gpcrs
WO2021140205A1 (en) 2020-01-10 2021-07-15 Confo Therapeutics N.V. Methods for generating antibodies and antibody fragments and libraries comprising same

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1589107E (pt) 1992-08-21 2010-03-29 Univ Bruxelles Imunoglobulinas desprovidas de cadeias leves
DK0698097T3 (da) 1993-04-29 2001-10-08 Unilever Nv Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
US5882944A (en) * 1993-06-23 1999-03-16 The Regents Of The University Of California Methods for G protein coupled receptor activity screening
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
AU740043B2 (en) 1996-06-27 2001-10-25 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Recognition molecules interacting specifically with the active site or cleft of a target molecule
AU3596599A (en) 1998-01-26 1999-08-09 Unilever Plc Method for producing antibody fragments
WO2000040968A1 (en) 1999-01-05 2000-07-13 Unilever Plc Binding of antibody fragments to solid supports
ATE276359T1 (de) 1999-01-19 2004-10-15 Unilever Nv Verfahren zur herstellung von antikörperfragmenten
CN100434441C (zh) 1999-04-22 2008-11-19 荷兰联合利华有限公司 利用单价抗原-结合蛋白抑制病毒感染
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
AU1859201A (en) 1999-11-29 2001-06-12 Unilever Plc Immobilisation of proteins
PT1233987E (pt) 1999-11-29 2009-12-28 Bac Ip B V Imobilização de moléculas de ligação ao antigénio de um domínio
ES2324280T3 (es) 2000-03-14 2009-08-04 Unilever N.V. Dominios variables de la cadena pesada de anticuerpos frente a lipasas dieteticas humanas y sus usos.
CA2380443C (en) 2000-05-26 2013-03-12 Ginette Dubuc Single-domain antigen-binding antibody fragments derived from llama antibodies
WO2002048193A2 (en) 2000-12-13 2002-06-20 Unilever N.V. Camelidae antibody arrays
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
US7371849B2 (en) 2001-09-13 2008-05-13 Institute For Antibodies Co., Ltd. Methods of constructing camel antibody libraries
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
AU2002360068B2 (en) 2001-12-21 2009-09-03 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Method for cloning of variable domain sequences
CA2471645A1 (en) 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Immunoconjugates useful for treatment of tumours
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
MXPA05007151A (es) 2002-12-31 2005-09-21 Nektar Therapeutics Al Corp Polimeros terminados en maleimida hidroliticamente estables.
CA2595682A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
DK1888641T3 (da) 2005-05-18 2012-04-23 Ablynx Nv Serumalbuminbindende proteiner
BRPI0609797B8 (pt) 2005-05-20 2021-05-25 Ablynx Nv nanocorpos melhorados para o tratamento de desordens mediadas por agregação
US8629244B2 (en) 2006-08-18 2014-01-14 Ablynx N.V. Interleukin-6 receptor binding polypeptides
EP2121757A2 (en) 2007-02-21 2009-11-25 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
CA2687903C (en) 2007-05-24 2016-09-13 Ablynx N.V. Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
FR2916977A1 (fr) * 2007-06-06 2008-12-12 Engelhard Lyon Sa STIMULATION DE LA SYNTHESE DES RECPTEURS MCR1, MCR2 ET µ OPIOIDE.
AU2009326075B2 (en) 2008-12-08 2014-06-05 Complix Nv Single-chain antiparallel coiled coil proteins
CN102257003B (zh) 2008-12-19 2017-04-05 埃博灵克斯股份有限公司 用于产生针对细胞相关抗原如p2x7、cxcr7或cxcr4的免疫球蛋白的基因免疫
WO2011083141A2 (en) 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
DK2611826T3 (en) 2010-08-30 2017-01-09 Confometrx Inc A method and composition for the crystallization of a family-C-GPCR
US8765414B2 (en) 2011-03-15 2014-07-01 The Board Of Trustees Of The Leland Stanford Junior University GPCR fusion protein containing an N-terminal autonomously folding stable domain, and crystals of the same
JP2014516963A (ja) 2011-05-13 2014-07-17 レセプトス インコーポレイテッド Ｇタンパク質共役レセプターを結晶化するための新規融合パートナー
CA2899693C (en) * 2013-01-30 2023-03-14 Vib Vzw Novel chimeric polypeptides for screening and drug discovery purposes
CA2936728C (en) 2014-01-30 2023-06-20 Vib Vzw Opioid receptor binding agents and uses thereof

Also Published As

Publication number Publication date
AU2015217846B2 (en) 2019-10-10
CA2936728C (en) 2023-06-20
WO2015121092A1 (en) 2015-08-20
US10233241B2 (en) 2019-03-19
EP3099707A1 (en) 2016-12-07
US20190338024A1 (en) 2019-11-07
US20170183404A1 (en) 2017-06-29
US11352422B2 (en) 2022-06-07
AU2015217846A1 (en) 2016-07-28
EP3099707B1 (en) 2021-12-29
JP2017506505A (ja) 2017-03-09
CA2936728A1 (en) 2015-08-20

Similar Documents

Publication Publication Date Title
US20250171510A1 (en) Binding Domains Directed Against GPCR:G Protein Complexes and Uses Derived Thereof
JP6687525B2 (ja) オピオイド受容体結合剤およびその使用
JP6827485B2 (ja) ムスカリン性アセチルコリン受容体の結合剤およびそれらの使用
JP2016504919A (ja) スクリーニングおよび薬物開発のための新規キメラポリペプチド

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181211

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190215

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20190527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190527

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191001

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200310

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200402

R150 Certificate of patent or registration of utility model

Ref document number: 6687525

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250